5 9 5 a r t I C l e S Acute pruritus, or itch, serves an important protective function by warning against harmful agents in the environment, such as insects, toxic plants or other irritants. Itch also promotes scratching, which aids in clearing pruritogens and attenuates itch sensations. However, pruritus can also be a debilitating condition that accompanies numerous skin, systemic and nervous system disorders 1 . Although many forms of itch are mediated by histamine signaling, there are clearly other important neural pathways. For example, a side effect of the antimalaria drug chloroquine is antihistamine-resistant, intolerable itch 2 . Similarly, spicules from the plant Mucuna pruriens produce intense itch via a histamine-independent pathway 3-5 . Moreover, immune cells release a variety of pruritogens that mediate allergyevoked itch, psoriasis and eczema, and antihistamines are not effective in treating the full spectrum of allergic disorders 6,7 . Finally, most pathophysiological itch conditions are insensitive to antihistamine treatment, and therapeutic targets have yet to be identified [8] [9] [10] [11] .
a r t I C l e S Acute pruritus, or itch, serves an important protective function by warning against harmful agents in the environment, such as insects, toxic plants or other irritants. Itch also promotes scratching, which aids in clearing pruritogens and attenuates itch sensations. However, pruritus can also be a debilitating condition that accompanies numerous skin, systemic and nervous system disorders 1 . Although many forms of itch are mediated by histamine signaling, there are clearly other important neural pathways. For example, a side effect of the antimalaria drug chloroquine is antihistamine-resistant, intolerable itch 2 . Similarly, spicules from the plant Mucuna pruriens produce intense itch via a histamine-independent pathway [3] [4] [5] . Moreover, immune cells release a variety of pruritogens that mediate allergyevoked itch, psoriasis and eczema, and antihistamines are not effective in treating the full spectrum of allergic disorders 6, 7 . Finally, most pathophysiological itch conditions are insensitive to antihistamine treatment, and therapeutic targets have yet to be identified [8] [9] [10] [11] .
Although the molecular and cellular mechanisms of itch have yet to be fully elucidated, recent studies have begun to delineate the basic characteristics of itch circuitry. There is now evidence implicating dedicated neuronal pathways for itch, separate from pain 12, 13 . Mice lacking gastrin-releasing peptide receptor (GRPR)-positive cells in the dorsal horn of the spinal cord display reduced itch behaviors but show normal pain behaviors 14 . Distinct subsets of primary afferent neurons mediating itch have also been identified. Approximately 5-20% of primary afferent C fibers are activated by endogenous itch-producing compounds released by non-neuronal cells in the skin (for example, mast cells), as well as by exogenous pruritogens, such as chloroquine 1, 15, 16 .
Itch-sensitive C fibers can be divided into subgroups based on pruritogen sensitivity. A subset of primary afferent C fibers that express the capsaicin receptor, TRPV1, can be divided into three groups based on receptor expression and pruritogen sensitivity. The first group expresses the 5-hydroxytryptamine receptor 3 and the H1 histamine receptor and mediates itch-evoked responses to serotonin and histamine 15 . The second group expresses Mas-related G protein-coupled receptor A3 (MrgprA3), which mediates itch-evoked responses to chloroquine. The third group expresses both MrgprA3 and MrgprC11, the receptor for the endogenous pruritogen BAM8-22 (BAM) 16 . MrgprA3 and MrgprC11 are members of the newly identified, sensory neuronspecific Mrgpr family. Although the function of most Mrgprs remains unknown, MrgprA3 and MrgprC11 have been shown to be important for histamine-independent pruritus. MrgprC11 is targeted by mast cell pruritogens released during allergic inflammation 17 . MrgprA3 is activated by chloroquine, which causes acute itch in rodents.
The signaling mechanisms by which pruritogen-evoked activation of MrgprA3 and MrgprC11 lead to neuronal excitation remain unknown. MrgprA3 and MrgprC11 are expressed in a subset of TRPV1-positive afferents. In addition, MrgprA3-evoked excitation is inhibited by ruthenium red, a blocker of TRPA1 and TRPV1 channels 16 . Although TRPV1-expressing afferents mediate responses to a variety of pruritogens and mice lacking functional TRPV1 channels display reduced responses to histamine, TRPV1-deficient mice display normal itch responses to serotonin and endothelin-1 (ref. 15) . These data imply that other ion channels are also activated by pruritogens in TRPV1-expressing afferents. These findings suggest that both TRPV1 and TRPA1 are candidate transduction channels in the Mrgpr pruritic pathways.
Itch, the unpleasant sensation that evokes a desire to scratch, accompanies numerous skin and nervous system disorders. In many cases, pathological itch is insensitive to antihistamine treatment. Recent studies have identified members of the Mas-related G protein-coupled receptor (Mrgpr) family that are activated by mast cell mediators and promote histamineindependent itch. MrgprA3 and MrgprC11 act as receptors for the pruritogens chloroquine and BAM8-22, respectively. However, the signaling pathways and transduction channels activated downstream of these pruritogens are largely unknown. We found that TRPA1 is the downstream target of both MrgprA3 and MrgprC11 in cultured sensory neurons and heterologous cells. TRPA1 is required for Mrgpr-mediated signaling, as sensory neurons from TRPA1-deficient mice exhibited markedly diminished responses to chloroquine and BAM8-22. Similarly, TRPA1-deficient mice displayed little to no scratching in response to these pruritogens. Our findings indicate that TRPA1 is an essential component of the signaling pathways that promote histamine-independent itch. a r t I C l e S The irritant receptor TRPA1 is highly expressed in a subset of TRPV1-positive neurons. TRPA1 is activated by a number of painproducing compounds, such as isothiocyanates (the pungent compounds present in mustard oil and other Brassica plants), cinnamon oil and cannabinoids. In addition, TRPA1 is activated downstream of G protein-coupled receptors (GPCRs), including the pro-algesic bradykinin receptor 18, 19 . Histamine, serotonin, chloroquine and BAM all evoke itch by acting on GPCRs 16, 20, 21 . Thus, TRPA1 is a key candidate transduction channel for itch.
We found that TRPA1 is essential for the transduction of Mrgprmediated itch. Cultured sensory neurons from TRPA1-deficient mice exhibited markedly diminished responses to both chloroquine and BAM. The functional coupling between MrgprA3 and TRPA1 was attenuated by disruption of Gβγ signaling, whereas coupling between MrgprC11 and TRPA1 required phospholipase C (PLC) signaling. TRPA1 was required for Mrgpr-evoked itch in vivo, as mice lacking TRPA1 did not display the chloroquine-or BAMevoked itch behaviors typical of wild-type animals. Our findings support an emerging role for TRP channels in the transduction of pruritic stimuli.
RESULTS

BAM and chloroquine activate TRPA1/TRPV1-positive neurons
The endogenous pruritogen BAM and the pruritic antimalaria drug chloroquine activate a subset of TRPV1-positive neurons 16 . To determine whether these pruritogens activate the subset of TRPV1-positive neurons that also express TRPA1, we used ratiometric Ca 2+ imaging to examine the overlap between BAM and chloroquine sensitivity and sensitivity to the TRPA1 agonist allyl isothiocyanate (mustard oil; Fig. 1 ). We found that 9.8 ± 1.2% of dorsal root ganglia (DRG) neurons and 16.1 ± 2.3% of trigeminal ganglia neurons (n ≥ 1,050 neurons; Fig. 1a -c) showed robust increases in intracellular Ca 2+ following chloroquine (1 mM) application, whereas only 6.2 ± 1.2% of DRG and 5.4 ± 0.9% of trigeminal neurons were responsive to both chloroquine and BAM (100 µM; n ≥ 390 neurons; Fig. 1a-c) . Subsequent exposure to mustard oil (200 µM) or capsaicin (1 µM) produced further increases in Ca 2+ levels in all chloroquine-and BAM-positive cells (Fig. 1b,c) . These results suggest that BAM and chloroquine activate a subset of TRPV1-positive sensory neurons that also express the ion channel TRPA1. To further test this, we used PCR to correlate Trpa1 gene expression with chloroquine and BAM sensitivity in individual sensory neurons, as determined by calcium imaging. Cells were subjected to RT-PCR using Mrgpra3, Mrgprc11 (also known as Mrgprx1) and Trpa1-specific primers. As previously reported, BAM-and chloroquine-sensitive neurons showed amplification of Mrgpra3 and Mrgprc11, respectively ( Fig. 1d and Supplementary Fig. 1) . Similarly, all BAM-sensitive neurons also expressed Mrgpra3 (n = 7), consistent with previous studies 22 and our imaging data ( Fig. 1b) . In addition, Trpa1 was amplified from all chloroquine-sensitive neurons (n = 7) and BAM-responsive neurons (n = 7) ( Fig. 1d and Supplementary Fig. 1 ). In contrast, BAM-, chloroquine-and mustard oil-insensitive cells did not display Mrgpra3, Mrgprc11 or Trpa1 expression ( Fig. 1d and Supplementary  Fig. 1) . These results indicate that chloroquine activates a subset of sensory neurons that express TRPA1 and TRPV1; BAM, in turn, activates a subset of chloroquine-sensitive cells.
Histamine and other PLC-coupled receptor agonists promote the release of Ca 2+ from intracellular stores and subsequent activation of TRP channels. Consistent with a previous study showing that the BAM receptor, MrgprC11, couples to PLC 23 , BAM application evoked Ca 2+ release from intracellular stores in the absence of extracellular Ca 2+ (Fig. 1e ). Subsequent addition of extracellular Ca 2+ triggered a rise in intracellular Ca 2+ as a result of influx ( Fig. 1e) . Unlike BAM, chloroquine application in the absence of extracellular Ca 2+ did not mobilize Ca 2+ release from stores. However, chloroquine application in extracellular Ca 2+ triggered influx across the plasma membrane ( Fig. 1f ). This suggests that both BAM and chloroquine trigger the influx of Ca 2+ through transduction channels in the plasma membrane. TRPV1 and TRPA1 are likely candidate transducers because they were expressed in chloroquine-and BAM-sensitive a r t I C l e S cells ( Fig. 1) and are inhibited by ruthenium red, which abolishes chloroquine-evoked signaling 16 . We therefore asked whether BAM-and chloroquine-evoked excitation is attenuated by pharmacological or genetic knockdown of TRPV1 or TRPA1 channels.
TRPV1 is not required for BAM or chloroquine signaling
We first compared BAM-and chloroquine-evoked Ca 2+ signals in neurons isolated from TRPV1-deficient mice to those isolated from wild-type littermates ( Fig. 2a-c) . Cultured neurons isolated from TRPV1-deficient mice showed a decrease in the proportion of BAMsensitive neurons ( Fig. 2a,c) but no change in the magnitude of the Ca 2+ signal in the responsive cells, as compared with wild type (wildtype peak, 1.38 ± 0.11; Trpv1 −/− peak, 1.52 ± 0.16; P = 0.59). Similar results were observed in wild-type neurons treated with the TRPV1 antagonist capsazepine (Fig. 2c) . In contrast, we found no differences in the amplitude (wild-type peak, 1.57 ± 0.18; Trpv1 −/− peak, 1.62 ± 0.21) or prevalence ( Fig. 2a,c) of chloroquine-evoked signals. Wildtype neurons treated with capsazepine displayed normal chloroquineevoked signals (Fig. 2c) .
To further probe the role of TRPV1 in chloroquine and BAM signaling, we next performed current-clamp recordings of chloroquine-and BAM-evoked action potential firing in wild-type and TRPV1-deficient neurons (Fig. 2d) . No significant differences in action potential firing were observed between wild-type and TRPV1-deficient neurons following application of BAM (wild type, 39.1 ± 10.5; Trpv1 −/− , 46.0 ± 15.0; P = 0.73; Fig. 2d ) or chloroquine (wild type, 8.0 ± 1.8; Trpv1 −/− , 7.2 ± 1.6; P = 0.74; Fig. 2d ). Taken together, these results demonstrate that functional TRPV1 channels are not required for BAM-or chloroquine-evoked excitation.
TRPA1 mediates BAM-and chloroquine-evoked excitation
We next asked whether deficiencies in TRPA1 would alter neuronal chloroquine and BAM sensitivity. Unlike TRPV1-deficient neurons that display a partial attenuation of BAM responses ( Fig. 2) , BAM-evoked Ca 2+ signaling is ablated in TRPA1-deficient neurons ( Fig. 3a-c) . Similarly, pharmacological inhibition of TRPA1 with the selective antagonist HC-030031 (100 µM) 24-26 significantly decreased neuronal sensitivity to BAM (Trpa1 +/+ , 6.18 ± 1.49; Trpa1 −/− , 1.12 ± 0.71, P = 0.002; HC-030031 treated, 0.57 ± 0.36, P = 0.001; Fig. 3c ).
We also examined the role of TRPA1 in chloroquine-evoked neuronal activation. Chloroquine-evoked Ca 2+ signals were significantly attenuated in TRPA1-deficient neurons (P = 0.0008; Fig. 3b ,c) as compared with wild-type neurons (Fig. 3b) . Consistent with previous studies, mustard oil-evoked responses were also attenuated in TRPA1-deficient neurons ( Fig. 3a,b) . Similarly, pharmacological inhibition of TRPA1 with HC-030031 significantly decreased neuronal sensitivity to chloroquine (P = 0.0008; Fig. 3c) . Notably, the prevalence of capsaicin-responsive cells was similar in wild-type, mutant and HC-030031-treated neurons (Trpa1 +/+ , 52.1 ± 5.17%; Trpa1 −/− , 56.7 ± 6.9%; HC-030031 treated, 55.5 ± 6.1%).
Finally, we used current-clamp recording to probe the role of TRPA1 in chloroquine-and BAM-evoked neuronal excitation. Chloroquine-and BAM-evoked action potential firing was compared in DRG neurons treated with vehicle versus HC-030031 ( Fig. 3d) . (a) Cultured sensory neurons isolated from wild-type and TRPV1-deficient mice were exposed to BAM (100 µM), followed by mustard oil (200 µM) and capsaicin (1 µM), and analyzed by Fura-2 ratiometric calcium imaging (representative responses). (b) Cultured sensory neurons isolated from wild-type and TRPV1-deficient mice were exposed to chloroquine (1 µM), followed by mustard oil (200 µM) and capsaicin (1 µM), and analyzed by Fura-2 ratiometric calcium imaging (representative responses). (c) The prevalence of chloroquine sensitivity was similar in wild-type (black), TRPV1-deficient (gray) and capsazepine-treated (CPZ, 20 µM, white) neurons. In contrast, the prevalence of BAM sensitivity was reduced in TRPV1-deficient (gray, P < 0.01, one-way ANOVA) and CPZ-treated neurons (white, P < 0.05, one-way ANOVA) relative to wild-type neurons (black). The prevalence of histamine (HIS) sensitivity was also reduced in TRPV1-deficient (gray, P < 0.05, one-way ANOVA) and CPZ-treated neurons (white, P < 0.05, one-way ANOVA; n = 3 animals per genotype, n ≥ 500 neurons per genotype) relative to wild-type neurons (black). Error bars represent s.e.m. (NS, not significant, P > 0.5; *P < 0.05, **P < 0.01, ***P < 0.001). (d) TRPV1 is not required for chloroquine-or BAM-evoked action potential firing. Representative current-clamp recording showing that wild-type and TRPV1-deficient neurons fired similar numbers of action potentials in response to BAM (100 µM) and chloroquine (1 mM) . No responses to capsaicin (1 µM) were observed in TRPV1-deficient neurons (n = 5-13 cells per genotype). a r t I C l e S TRPA1 inhibition significantly attenuated chloroquine-evoked action potential firing (vehicle, 6.2 ± 1.2; HC-030031, 0.25 ± 0.1; P = 0.003; Fig. 3d ) and BAM-evoked firing (vehicle, 21.3 ± 4.2; HC-030031, 2.40 ± 0.98; P = 0.002; data not shown). Together, our results indicate that functional TRPA1 channels are required for chloroquine-and BAM-evoked neuronal excitability.
Although TRPA1 is required for chloroquine and BAM signaling, it does not mediate all forms of itch. Neurons isolated from TRPA1deficient animals ( Fig. 3c ) or neurons treated with HC-030031 ( Fig. 3c ) display normal histamine-evoked responses. These findings are consistent with previous studies showing that TRPV1, but not TRPA1, is required for histamine signaling in sensory neurons 15, 27, 28 .
MrgprA3 and MrgprC11 functionally couple to TRPA1
The GPCRs MrgprA3 and MrgprC11 are required for chloroquine and BAM signaling in sensory neurons, respectively 16 . In addition to being activated directly by endogenous and exogenous irritants, TRPA1 is a receptor-operated channel that can be activated by bradykinin or other GPCR-coupled inflammatory mediators 29, 30 . We therefore asked whether chloroquine or BAM could activate heterologous TRPA1 channels expressed in the chloroquine-and BAM-insensitive neuroblastoma cell line, NG108. Chloroquine and BAM did not trigger Ca 2+ influx into Trpa1-transfected cells (Fig. 4a) . However, these cells responded robustly to application of mustard oil (200 µM; Fig. 4a ), confirming the presence of functional TRPA1 channels. Chloroquine-evoked Ca 2+ signals were not observed in NG108 cells transfected with Mrgpra3 alone (Fig. 4a,b) . Consistent with our findings in TRPV1-deficient neurons (Fig. 2) , chloroquine also failed to trigger Ca 2+ signals in cells expressing Mrgpra3 and Trpv1 (Fig. 4b) . In contrast, NG108 cells transfected with both Trpa1 and Mrgpra3 displayed robust increases in intracellular Ca 2+ following chloroquine application (Fig. 4a,b) ; these responses were attenuated by HC-030031 (data not shown). Thus, both MrgprA3 and TRPA1 receptors are required to confer chloroquine sensitivity to NG108 cells.
BAM-evoked Ca 2+ signals were observed in NG108 cells transfected with Mrgprc11 alone, but not in cells transfected with Trpa1, Trpv1 or vector alone (Fig. 4c) . This is consistent with our finding that MrgprC11 activation led to Ca 2+ release from stores ( Fig. 1e) and previous studies linking MrgprC11 and PLC 31 . Co-transfection of Trpv1 with Mrgprc11 caused an increase in the amplitude of the BAM response (30.1% increase, P = 0.005; Fig. 4c ). However, coexpression of Trpa1 with Mrgprc11 led to an even more robust increase in intracellular Ca 2+ , 81% higher than with Mrgprc11 alone (P = 0.0001; Fig. 4c ). These data suggest that both TRPV1 and TRPA1 couple to MrgprC11, consistent with our findings that both channels contribute to BAM-evoked Ca 2+ responses in neurons ( Figs. 2c and 3c) .
MrgprA3 and MrgprC11 couple to TRPA1 via distinct mechanisms
We next examined the mechanisms by which MrgprA3 preferentially activates TRPA1 but not TRPV1. Because many TRP channels are activated or modulated by PLC-coupled receptors 32 and many pruritogens and members of the Mrgpr family activate PLC signaling 23 , we first tested the role of PLC in chloroquine-evoked signaling. (a) Cultured sensory neurons isolated from wild-type and TRPA1deficient mice were exposed to BAM (100 µM), followed by mustard oil (200 µM) and capsaicin (1 µM), and responses were measured by Fura-2 ratiometric calcium imaging (representative responses). (b) Cultured sensory neurons isolated from wild-type and TRPA1-deficient mice were exposed to chloroquine (1 µM), followed by mustard oil (200 µM) and capsaicin (1 µM), and responses were measured by Fura-2 ratiometric calcium imaging (representative responses). (c) The prevalence of chloroquine sensitivity was significantly reduced in TRPA1-deficient (gray, P < 0.01, one-way ANOVA) and HC-03001-treated neurons (white, 100 µM, P < 0.001, one-way ANOVA) relative to wild-type neurons (black). Similarly, the prevalence of BAM sensitivity was reduced in TRPA1-deficient (gray, P < 0.001, one-way ANOVA) and HC-030031-treated neurons (white, P < 0.001, one-way ANOVA) relative to wild type (black). In contrast, the prevalence of histamine sensitivity was similar in wild-type (black), TRPA1-deficient (gray, P = 0.73, one-way ANOVA) and HC-030031-treated neurons (white, P = 0.61, one-way ANOVA, n = 3 animals per genotype, n ≥ 500 neurons per genotype). NS, not significant, P > 0.5; **P < 0.01, ***P < 0.001. Error bars represent s.e.m. (d) TRPA1 is required for chloroquine-evoked action potential firing. Representative current-clamp recording showed that HC-03001 (100 µM) blocked chloroquine-evoked action potential firing (n ≥ 5 cells per compound).
a r t I C l e S
The PLC inhibitor U73122 had no effect on the amplitude (Fig. 5a ) or prevalence (Fig. 5b) of chloroquine-evoked Ca 2+ signals in cultured neurons or in NG108 neurons transfected with both Trpa1 and Mrgpra3 (data not shown). BAM activation of MrgprC11 has been previously demonstrated to act through PLC 23 . Consistent with these findings, U73122 reduced both the amplitude of BAMevoked Ca 2+ signals in cultured neurons (Fig. 5b ) and the prevalence of BAM-sensitive neurons (Fig. 5c) . Similarly, U73122 significantly attenuated histamine signaling in neurons (P = 0.010; Fig. 5c ). These data indicate that although PLC signaling is required for BAM-and histamine-evoked signaling, it is not required for MrgprA3-mediated activation of TRPA1. GPCR signaling leads to the dissociation of not only Gα, but also Gβγ, subunits. Gβγ signaling has been shown to directly open ion channels 33 . Thus, we asked whether Gβγ signaling is required for MrgprA3-evoked activation of TRPA1. Pre-treatment of neurons with gallein, a small molecule inhibitor of Gβγ, markedly reduced both the amplitude of chloroquine-evoked Ca 2+ signals (Fig. 5a ) and the number of chloroquine-sensitive cells (vehicle, 17.6 ± 1.1%; gallein, 4.6 ± 1.1%; Fig. 5c ). Gallein does not act directly on TRPA1, as mustard oil-evoked activation of TRPA1 was not altered by a r t I C l e S this inhibitor (data not shown). Similarly, gallein has no effect on histamine-evoked signaling in neurons (Fig. 5c) . We also probed the role of Gβγ in chloroquine-evoked neuronal excitation using currentclamp recording. Gallein significantly attenuated action potential firing caused by chloroquine application (vehicle, 17.00 ± 13.24; 100 µM gallein, 1.33 ± 1.53; P = 0.003; Fig. 5d ). Finally, we explored the role of Gβγ in the coupling between MrgprA3 and TRPA1 in heterologous cells. Coexpression of phosducin (Pdc), a Gβγ chelating peptide 34 , or treatment with gallein significantly attenuated chloroquine responses in NG108 cells (control, 82.34 ± 9.61% phosducin, 58.21 ± 11.61%; P = 0.003; Fig. 5e and data not shown). These findings suggest that Gβγ signaling is required for MrgprA3 coupling to TRPA1. Gβγ signaling has also been shown to open channels via PLC 35, 36 . Thus, we asked whether Gβγ signaling is also required for the PLCdependent coupling between MrgprC11 and TRPA1. Pre-treatment of neurons with gallein had no effect on the amplitude of BAM-evoked Ca 2+ signals (Fig. 5b) or the fraction of BAM-sensitive cells (vehicle, 7.06 ± 1.94%; U73122, 0.98 ± 0.95%; gallein, 6.54 ± 3.46%; Fig. 5c ). Similarly, overexpression of Pdc in NG108 cells transfected with both Trpa1 and Mrgprc11 did not attenuate BAM-evoked responses (control, 82.37 ± 6.55%; phosducin, 81.95 ± 6.11%; P = 0.887; Fig. 5e) . These experiments provide evidence that PLC signaling through Gα q is required for MrgprC11-evoked neuronal activation and may explain why MrgprC11 can couple to both TRPA1 and TRPV1, similar to the bradykinin receptor 19, 29 .
TRPA1 is required for chloroquine-and BAM-evoked itch Given the requirement for TRPA1 in the cellular actions of chloroquine and BAM, we asked whether TRPA1-deficient mice also exhibit behavioral deficits in chloroquine-and BAM-evoked itch. Chloroquine and BAM injection into the nape of the neck evoked robust scratching behaviors in wild-type mice (Fig. 6a) . The time spent scratching was significantly attenuated in TRPA1-deficient littermates to levels similar to those seen in wild-type mice that received vehicle injections (chloroquine, P = 0.0039; BAM, P = 0.0038; Fig. 6a) . In contrast, no differences between wild-type mice and TRPV1deficient littermates were observed for either chloroquine or BAM injection (chloroquine, P = 0.619; BAM, P = 0.138; Fig. 6a) . These results suggest that although TRPV1 partially contributes to the cellular responses to BAM in culture, the residual BAM sensitivity in TRPV1-deficient neurons drives BAM-evoked itch behaviors and requires functional TRPA1 channels.
To distinguish between chloroquine-and BAM-evoked itch and pain behavior, we used the cheek model of itch, where an irritant is injected into the cheek, rather than into the neck 37 . Injection of chloroquine or BAM evoked robust scratching of the cheek with the hindlimb (Fig. 6b,c and Supplementary Movie 1) . In contrast, injection of an irritant, such as mustard oil (1 mM), evoked wiping of the cheek with one of the forelimbs (Fig. 6b) . Standard grooming behaviors always involve rubbing the head or face with both forelimbs. Wiping was never observed following injection of chloroquine or BAM. Thus, we used this model to better examine the in vivo role of TRPA1 in chloroquine-and BAM-evoked itch. In the cheek assay, chloroquine and BAM evoked prolonged periods of scratching in wild-type mice. No significant differences were observed between Trpa1 +/+ mice and Trpv1 +/+ mice (BAM: Trpa1 +/+ , 49.2 s; Trpv1 +/+ , 50.5 s; P = 0.90, one-way ANOVA; chloroquine: Trpa1 +/+ , 111 s; Trpv1 +/+ , 104.8 s; P = 0.94) and we therefore combined data from these animals ( Fig. 6c) . Similarly, no significant differences in BAM-or chloroquine-evoked scratching were observed between wild-type and TRPV1-deficient mice (BAM, P = 0.850; chloroquine, P = 0.352; Fig. 6c ). In contrast, this scratching behavior was never observed in TRPA1-deficient mice (Fig. 6c) . TRPA1-deficient mice were not generally incapable of scratching or insensitive to all pruritogens, as cheek injection of alpha-methyl-serotonin (2 µM) evoked robust scratching (wild type, 48.3 ± 10.8 s; Trpa1 −/− , 51.0 ± 10.4 s; P = 0.87, n = 11 mice per genotype). These findings suggest that TRPA1 is required for both chloroquine-and BAM-evoked itch.
DISCUSSION
Itch is mediated by both histamine-dependent and histamineindependent pathways. Chronic itch associated with skin and systemic diseases is insensitive to antihistamine treatment and even allergic itch is only marginally inhibited by histamine receptor antagonists 38 . However, little is known about the mechanisms underlying histamine-independent itch. The GPCRs MrgprA3 and MrgprC11 are receptors for chloroquine and BAM, respectively, two pruritogens a r t I C l e S that elicit robust antihistamine-insensitive itch 16, 39 . Our results clearly demonstrate that TRPA1 is activated downstream of both MrgprA3 and MrgprC11 and is the primary transduction channel mediating chloroquine-and BAM-evoked signaling and itch behaviors. Most Mrgprs are orphan GPCRs and the underlying mechanisms by which they mediate signal transduction are largely unknown. However, MrgprC11 has been shown to couple to the Gα q/11 pathway and activate PLC in heterologous cells 23 . Consistent with these findings, we found that MrgprC11-evoked excitation requires functional PLC signaling in neurons. Most TRP channels are activated or modulated by PLC, making them likely downstream targets of MrgprC11. Indeed, MrgprC11-positive BAM-sensitive neurons expressed both TRPA1 and TRPV1. Thus, it is not surprising that BAM activated both TRPA1 and TRPV1 in heterologous cells or that both channels contributed to BAM-evoked calcium signals in neurons. It is surprising, however, that TRPA1, but not TRPV1, was required for BAM-evoked itch behaviors. This finding is similar to bradykinin-evoked signaling, in which PLC robustly activates TRPA1 and weakly activates TPRV1 to promote calcium influx; because calcium also activates TRPA1 (refs. 40,41) , calcium permeation through TRPV1 opens additional TRPA1 channels, ultimately leading to mechanical and thermal hypersensitivity. Similar to BAM, loss of TRPV1 or TRPA1 leads to diminished bradykinin-evoked calcium signaling in vitro, but only the loss of TRPA1 leads to attenuation of inflammatory behavioral responses. Thus, TRPA1 has a dominant role in both bradykinin and BAM signaling in vivo.
Unlike BAM, pharmacological inhibition of PLC did not alter chloroquine-evoked activation of TRPA1 in sensory neurons or transfected cell lines. These findings are consistent with a previous study showing that chloroquine-evoked itch is normal in mice lacking PLCβ 15 . In addition, chloroquine-evoked signaling did not require functional TRPV1 channels in neurons and MrgprA3 failed to couple to TRPV1 in heterologous cells. What signaling pathway mediates the functional coupling of MrgprA3 to TRPA1 but not to TRPV1? In somatosensation, Gβγ is required for morphine-evoked analgesia and directly activates N-and P/Q-type calcium channels in cultured DRG neurons 42, 43 . We found that Gβγ may be yet another signaling molecule capable of modulating the activity of a TRP channel. Gallein, a small molecule inhibitor of Gβγ, and the Gβγ chelating peptide, phosducin, specifically attenuated chloroquine-evoked signaling with no effects on histamine or BAM signaling. Taken together, these data indicate that Gβγ is a likely candidate for mediating the specific coupling of MrgprA3 and TRPA1. Gβγ modulates several ion channels via direct binding, including members of the G protein-coupled inwardly rectifying potassium channel and voltage-gated calcium channel families 33 . Future studies will elucidate whether Gβγ opens TRPA1 channels directly or via signaling intermediates.
Our findings support the hypothesis that TRP channels are key mediators of both pain and itch. Previous studies have shown that TRPV1 is a primary transducer of histamine-evoked itch 15, 28 . However, among TRPV1-positive neurons, only a subset expresses histamine receptors and transduces itch. Similarly, only a subset of TRPA1-positive neurons coexpressed MrgprA3 and responded to chloroquine, and an even smaller subset of these cells expressed MrgprC11 and responded to BAM. The molecularly distinct subsets of TRPA1-positive neurons that transduce BAM and chloroquine itch signals support the labeled line theory of itch in which distinct pruritogens use a dedicated pathway to transduce itch signals. In contrast, the identification of TRPA1 as a key transducer of itch and pain also supports the spatial contrast theory of itch, whereby itch is triggered by the activation of a small number of pain fibers in a receptive field and pain is initiated when a larger cohort of cells is activated 44 . As with TRPA1 and TRPV1, MrgprC11 has been proposed to be involved not only in itch but also in hyperlagesia 45 . In addition, several studies have described the inhibition of itch by painful chemical or mechanical stimuli 1, 46, 47 . Strong support of both itch theories has led to a modified 'selectivity' theory of itch 1 that incorporates aspects of both itch models. The recent discovery of itch-specific spinal cord neurons suggests that central circuits may generate the specificity observed in itch signaling 47, 48 . However, the relationship between itch and pain remains a pressing question in somatosensation. Understanding the molecular mechanisms underlying both itch and pain is a first step toward understanding this complex relationship.
Our results suggest a previously unknown role for TRPA1 in chloroquine-evoked itch. A major side effect of the MrgprA3 agonist and anti-malarial drug chloroquine is intolerable itch. Chloroquine is cheap, easy to administer and highly effective in both treating and preventing malaria. Indeed, the demand for chloroquine is on the rise; a recent study has shown a decrease in chloroquineresistant Plasmodium falciparum 49 . However, chloroquine-evoked itch, which is especially prevalent among dark-skinned Africans (up to 70%), is a major cause of poor compliance and treatment defaulting 2 . Differences in pruritic responses to chloroquine may result from polymorphic differences in the Mrgpr signaling pathway or in the TRPA1 gene, such as in familial episodic pain syndrome, which has been recently linked to gain of function mutations in TRPA1 (ref. 50 ). In such cases, improved therapeutics employing inhibition of MrgprA3 or TRPA1 aimed at alleviating chloroquine-induced itch may enable chloroquine to remain a useful and relevant treatment in Africa.
Aside from chloroquine, chronic itch results from skin diseases and systemic conditions, such as eczema, cirrhosis and some cancers, diabetes, as well as neurological disorders, including multiple sclerosis, post-herpetic neuralgia and, perhaps the most prevalent, allergic inflammation. Mast cell-neuronal interactions are known to be important in all of these pruritic conditions. Mast cells are in close association with peripheral nerve endings and release a variety of pruritic factors that act on sensory neurons. MrgprA4 and MrgprC11 are both activated by neuropeptide FF, a pruritogen released from mast cells during allergy-induced mast cell degranulation 16, 17 . These findings indicate that endogenous pruritogens target members of the Mrgpr family and our findings demonstrate an essential role for MrgprC11, and therefore TRPA1, in allergic mast cell-mediated inflammation.
Perhaps most importantly, our findings suggest that TRPA1 is a downstream transduction channel onto which multiple histamineindependent itch pathways converge. BAM and chloroquine lead to TRPA1 activation via two distinct signaling pathways. Our behavioral studies revealed a marked loss of itch-evoked behaviors in TRPA1deficient animals in response to both of these pruritogens. As such, TRPA1 antagonists may be useful for the selective attenuation of antihistamine-insensitive itch, a problem that is especially relevant to pathological itch conditions. Whether MrgprA3, MrgprC11 and TRPA1 signaling contributes to chronic itch is unknown. Mrgpr-and TRPA1-deficient mice now provide a genetic model with which to assess the mechanisms of intractable itch.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
